Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Usona has filed a New Drug Application for its psilocybin depression treatment, intensifying the competitive race with Compass Pathways for FDA approval.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A significant development in the psychedelic pharmaceutical sector has emerged as Usona has officially filed a New Drug Application (NDA) for its psilocybin-based treatment for depression. This move directly accelerates the competition between Usona and Compass Pathways, two prominent firms vying to bring the first psychedelic therapy to market. The filing marks a critical regulatory step in the quest to secure official approval for psilocybin as a clinical intervention for depressive disorders, creating a high-stakes environment for both organizations as they seek a first-mover advantage in the medical field. Coverage of this race is being tracked by a variety of outlets including Psychedelic Alpha, which detailed the NDA filing, and STAT, which is examining the broader question of which company will ultimately secure the first psychedelic approval. Financial news sources such as Yahoo Finance have reported that shares of CMPS and HELP are on track for their worst day in months.
This market volatility is attributed to investor fears regarding the intensifying competitive landscape of the FDA psychedelic race. Simultaneously, Moomoo has distributed a press release regarding the third quarter 2026 financial results and business highlights for Compass Pathways. Context for this trend is found in the broader pursuit of FDA-approved psychedelic medicines. The competition is not merely about scientific discovery but about the commercial viability and market dominance that comes with being the first approved provider. The Motley Fool has noted that Compass Pathways remains a company worth a second look this month despite the increased pressure.
The current volatility in stock prices reflects the sensitivity of the market to regulatory milestones and the potential for one company to leapfrog another in the approval process for psilocybin treatments. Future developments to watch include the FDA's response to Usona's NDA filing and the progression of Compass Pathways' own regulatory timeline. Observers will be monitoring whether the competitive pressure results in further shifts in stock performance for CMPS and HELP. The industry remains focused on the specific timelines for approval and the subsequent business highlights that will emerge from the third quarter 2026 financial data. The primary objective for these firms remains the transition from experimental trials to a legally approved pharmaceutical product for depression.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 11d ago.
Quick answers
What action did Usona recently take?
Usona has filed a New Drug Application (NDA) for its psilocybin treatment for depression.
Which stocks have seen a significant decline according to Yahoo Finance?
CMPS and HELP stocks were on track for their worst day in months due to fears over the competitive FDA psychedelic race.
What recent information did Compass Pathways release?
Compass Pathways announced its third quarter 2026 financial results and business highlights via a press release reported by Moomoo.
Coverage (5)
- 1 Reason Compass Pathways Is Worth a Second Look This Month The Motley Fool · 14d ago
- Press Release: Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights Moomoo · 14d ago
- Who will get the first psychedelic approved? STAT · 14d ago
- CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fears Yahoo Finance · 14d ago
- Usona Files Psilocybin for Depression NDA as Race With Compass Tightens Psychedelic Alpha · 14d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk announces trial data showing Wegovy injection reduces BMI and obesity rates in children as young as six, expanding weight-loss drug use to elementary-age patients.
The GLP-1 boom has a dark side
The FDA orders eye risk warnings on GLP-1 medications like Ozempic and Zepbound, prompting expert guidance.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
Scientists Discovered a Mushroom That's Both Toxic and Trippy
Scientists discovered a mushroom in Florida that contains both toxic and psychedelic compounds